Vaxart, Inc.
Biological Products, (No Diagnostic Substances) · 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
官方登记数据
0位关注者
2004成立于
关于 Vaxart, Inc.
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Source: Wikipedia
行业Biological Products, (No Diagnostic Substances)
总部310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
成立2004
法律形式C Corporation
状态营业中
专利58 项专利
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A3 · 2026
ANTIBODIES TARGETING GII GENOTYPES OF HUMAN NOROVIRUSWO2025255258A2 · 2025
关键数据
法律信息
| 法定名称 | Vaxart, Inc. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 72444在 SEC EDGAR 上查看 ↗ |
| EIN | 59-1212264 |
| 行业代码(SIC) | 2836 |
| 注册地址 | 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA |
| 状态 | 营业中 |
来源: SEC EDGAR · 更新于 Oct. 15, 2026
联系方式和链接
地点
310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
这是你的公司吗?
免费认领此页面,即可添加标志、产品、照片和职位,并回复评价。
认领此页面